NasdaqGM:PTGXBiotechs
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After A 107% One-Year Surge?
Investors may be wondering whether Protagonist Therapeutics at around US$102 still offers value, or if most of the opportunity is already priced in.
The stock has posted returns of 0.5% over the last 7 days, 16.9% over the last 30 days, 17.2% year to date and 106.7% over the last year. This naturally raises questions about how much of the story is already reflected in the share price.
Recent news flow around Protagonist Therapeutics has focused on its progress as a biotech name and how the...